Missed Estimates News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The analysts might have been a bit too bullish on InMode Ltd. ( NASDAQ:INMD ), given that the company fell short of...

Lamb Weston Holdings, Inc. ( NYSE:LW ) just released its latest quarterly report and things are not looking great...

Lucid Group forecast annual vehicle production far below analysts' estimates on Wednesday, on signs that demand for its luxury electric vehicles will slow down as high interest rates pinch consumer budgets. Shares of the company fell around 5% in extended trading. The company expects to make 9,000 units for the full-year 2024 compared with estimates of 22,594 according to five analysts polled by Visible Alpha.

(Reuters) -Biogen on Tuesday forecast flat 2024 product revenue as top-selling drugs face tough competition and sales of newer treatments take off slowly, but said there are signs its new Alzheimer's drug is gaining traction. Shares of the U.S. biotech fell 7% as it missed Wall Street expectations for quarterly revenue and projected sales for this year that several analysts found underwhelming. Sales of pricey spinal muscular atrophy drug Spinraza, which is dealing with fresh competition, also missed estimates.

While Starbucks saw a strong start to the quarter with a 5.9% rise in traffic at its U.S. stores in October, the momentum quickly faded with November and December posting declines of 5.1% and 4.5%, respectively, brokerage Wells Fargo noted citing Placer.ai data. "Investors probably must have expected worse and this is a better-than-feared situation where, while things aren't good, they're not as bad as they could have been," M Science analyst Matthew Goodman said. Starbucks saw a "significant impact to traffic and sales" in the Middle East due to the Israel-Hama...